Lymphovascular Invasion Is Associated With Doxorubicin Resistance in Breast Cancer

被引:0
|
作者
Corachea, Allen Joy M. [1 ]
Ferrer, Regina Joyce E. [1 ]
Ty, Lance Patrick B. [1 ]
Aquino, Lizzie Anne C. [2 ]
Morta, Madeleine T. [1 ]
Macalindong, Shiela S. [2 ]
Uy, Gemma Leonora B. [2 ]
Odono, Eugene G. [3 ]
Llames, Jo-Hannah S. [4 ]
Tablizo, Francis A. [4 ]
Paz, Eva Maria C. Cutiongco-Dela [5 ]
Dofitas, Rodney B. [2 ]
Velarde, Michael C. [1 ]
机构
[1] Univ Philippines Diliman, Inst Biol, Coll Sci, Quezon City, Philippines
[2] Univ Philippines Manila, Philippine Gen Hosp, Dept Surg, Manila, Philippines
[3] Univ Philippines Manila, Philippine Gen Hosp, Dept Pathol, Manila, Philippines
[4] Univ Philippines, Philippine Genome Ctr, Quezon City, Philippines
[5] Univ Philippines Manila, NIH, Manila, Philippines
关键词
breast cancer; lymphovascular invasion; drug resistance; patient-derived organoids; SURGICAL ADJUVANT BREAST; NEOADJUVANT TREATMENT; ENRICHMENT ANALYSIS; CYP1B1; INHIBITORS; DOCETAXEL; DISEASE; MODELS;
D O I
10.1016/j.labinv.2025.104115
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Lymphovascular invasion (LVI), the invasion of tumor cells into the lymphatic or vascular space, is an early indicator of potential metastasis, with its presence in breast cancer independently predicting poorer outcomes even after neoadjuvant chemotherapy. However, a major limitation is that LVI detection currently relies on postsurgical evaluation. To address this, we determined whether LVI+ breast tumors contain a unique gene signature that could facilitate earlier detection. Here, we conducted an integrative analysis of the gene profile between LVI+ and LVI- primary breast tumors from various sources, including published data and our own research, using both microarray and RNA-seq data. Our analysis revealed protein binding and vesicle-related genes to be the most enriched categories in LVI+ vs LVI- tumors. Furthermore, LVI+ tumors showed enrichment for xenobiotic metabolism genes, particularly drug metabolism enzymes, such as cytochrome P450 and uridine 5'-diphospho-glucuronosyltransferases. An elastic net regression model containing 13 of these uridine 5'-diphospho-glucuronosyltransferases and cytochrome P450 genes can predict LVI status with 92% accuracy. This suggests a potential link to drug resistance, which was further confirmed by the finding that patients with LVI+ tumors had a significantly lower clinical response rate than individuals with LVI- tumors. We also observed this resistance in patient-derived organoids, with LVI+ organoids exhibiting lower sensitivity to doxorubicin, implying that doxorubicin might be less effective for LVI+ breast cancer, potentially contributing to poorer outcomes. Overall, our study unlocked an exciting opportunity for personalized medicine, in that, therapy efficacy and patient outcomes can be improved by incorporating the LVI-associated gene signature into treatment plans. (c) 2025 United States & Canadian Academy of Pathology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Calpastatin is associated with lymphovascular invasion in breast cancer
    Storr, Sarah J.
    Mohammed, Rabab A. A.
    Woolston, Caroline M.
    Green, Andrew R.
    Parr, Tim
    Spiteri, Inmaculada
    Caldas, Carlos
    Ball, Graham R.
    Ellis, Ian O.
    Martin, Stewart G.
    BREAST, 2011, 20 (05): : 413 - 418
  • [2] Hormone use is associated with lymphovascular invasion in breast cancer
    Loof-Johanson, M.
    Brudin, L.
    Rudebeck, C. E.
    Sundquist, M.
    BREAST, 2017, 32 : S46 - S47
  • [3] Chromosomal aberrations associated with lymphovascular invasion in breast cancer
    Sundquist, M.
    Brudin, L.
    Johansson, S.
    Stal, O.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S300 - S300
  • [4] Updates on Lymphovascular Invasion in Breast Cancer
    Kuhn, Elisabetta
    Gambini, Donatella
    Despini, Luca
    Asnaghi, Dario
    Runza, Letterio
    Ferrero, Stefano
    BIOMEDICINES, 2023, 11 (03)
  • [5] A key genomic subtype associated with lymphovascular invasion in invasive breast cancer
    Sasagu Kurozumi
    Chitra Joseph
    Sultan Sonbul
    Sami Alsaeed
    Yousif Kariri
    Abrar Aljohani
    Sara Raafat
    Mansour Alsaleem
    Angela Ogden
    Simon J Johnston
    Mohammed A Aleskandarany
    Takaaki Fujii
    Ken Shirabe
    Carlos Caldas
    Ibraheem Ashankyty
    Leslie Dalton
    Ian O Ellis
    Christine Desmedt
    Andrew R Green
    Nigel P Mongan
    Emad A Rakha
    British Journal of Cancer, 2019, 120 : 1129 - 1136
  • [6] A key genomic subtype associated with lymphovascular invasion in invasive breast cancer
    Kurozumi, Sasagu
    Joseph, Chitra
    Sonbul, Sultan
    Alsaeed, Sami
    Kariri, Yousif
    Aljohani, Abrar
    Raafat, Sara
    Alsaleem, Mansour
    Ogden, Angela
    Johnston, Simon J.
    Aleskandarany, Mohammed A.
    Fujii, Takaaki
    Shirabe, Ken
    Caldas, Carlos
    Ashankyty, Ibraheem
    Dalton, Leslie
    Ellis, Ian O.
    Desmedt, Christine
    Green, Andrew R.
    Mongan, Nigel P.
    Rakha, Emad A.
    BRITISH JOURNAL OF CANCER, 2019, 120 (12) : 1129 - 1136
  • [7] Telomerase activity and lymphovascular invasion in breast cancer
    Mokbel, KM
    Parris, CN
    Ghilchik, M
    Amerasinghe, CN
    Newbold, RF
    EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 2000, 26 (01): : 30 - 33
  • [8] Are Perineural Invasion and Lymphovascular Invasion Significant Predictors of Breast Cancer Outcomes?
    Paul, Dale
    Belay, Claire
    Scott, Anthony
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (SUPPL 2) : S245 - S246
  • [9] Diagnostic concordance of reporting lymphovascular invasion in breast cancer
    Rakha, Emad A.
    Abbas, Areeg
    Pinto Ahumada, Pablo
    ElSayed, Maysa E.
    Colman, Derek
    Pinder, Sarah E.
    Ellis, Ian O.
    JOURNAL OF CLINICAL PATHOLOGY, 2018, 71 (09) : 802 - 805
  • [10] Significance of Extensive Lymphovascular Space Invasion in Breast Cancer
    Rakhra, S.
    Gutiontov, S.
    Dalal, P.
    Bell, J. B.
    Butala, A.
    Donnelly, E. D.
    Hayes, J. P.
    Gius, D. R.
    Helenoswki, I.
    Strauss, J. B.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : E43 - E43